Exhibit 99.1
NEWS RELEASE
| Contact: | Jennifer Chmieleski | |
| Vice President and Controller | ||
| (978) 206-8220 | ||
| Jenniferc@psychemedics.com |
PSYCHEMEDICS CORPORATION ANNOUNCES SECOND QUARTER RESULTS
$0.17 DIVIDEND DECLARED
Acton, Massachusetts, July 28, 2008 — Psychemedics Corporation (AMEX:PMD) today announced second quarter financial results for the period ended June 30, 2008. The Company also announced a quarterly dividend of $0.17 per share payable to shareholders of record as of September 5, 2008 to be paid on September 19, 2008. This will be the Company’s 48th consecutive quarterly dividend.
The Company’s second quarter revenue was $6.2 million, down 4% as compared to $6.5 million in the second quarter of 2007. Net income was $1.0 million or $0.20 per diluted share, down 23% from $1.3 million or $0.25 per share for the same period in 2007. The Company’s revenue for the six months ended June 30, 2008 was $11.9 million, down 2% as compared to $12.2 million for the comparable period of 2007. Net income for the six months ended June 30, 2008 was $1.9 million or $0.36 per diluted share, a decrease of 19% over the comparable period last year during which the Company earned $2.4 million or $0.45 per share.
Raymond C. Kubacki, Chairman and Chief Executive Officer, said, “The jobs market remains a challenge, as the economy continues to see significant job losses through June — in fact, six months of declines in a row. However, our revenues were off only slightly due to the fact that we continue to add new clients, thereby offsetting the weakness in hiring.”
Kubacki continued, “We continue to make the investments in our sales and marketing in order to capitalize on significant future growth opportunities. This increased expense, as well as an increase in our legal expenses as compared to the same period last year, have caused our net income to be below our historic levels. However, despite these investments, we continue to report strong margins and strong earnings in a tough economic environment.”
Kubacki concluded, “The Company continues to have a strong balance sheet with approximately $9.5 million of cash and investments and no long-term debt. We continue to stay focused and we remain confident in our future growth. Therefore, we are declaring our 48th consecutive quarterly dividend. This dividend demonstrates our Directors’ confidence in the future and continued commitment to rewarding shareholders as we move forward.”
On March 17, 2008, the Company announced the authorization of a 250,000 share stock repurchase program.
Psychemedics is the world’s largest provider of hair testing for drugs of abuse with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics’ clients include over 10% of the Fortune 500, some of the largest police departments in America and six Federal Reserve Banks.
Financial Summary
| • | Revenue for the second quarter of $6.2 million, down 4% from the prior year quarter | ||
| • | Revenue for the six month period of $11.9 million, down 2% from the prior year period | ||
| • | Pretax income for the second quarter of $1.7 million, down 22% from the prior year quarter | ||
| • | Pretax income for the six month period of $3.2 million, down 18% from the prior year period | ||
| • | Net income for the second quarter of $1.0 million, or $0.20 per diluted share, down 23% from the prior year quarter | ||
| • | Net income for the six month period of $1.9 million, or $0.36 per diluted share, down 19% from the prior year period |
The Psychemedics web site iswww.drugtestwithhair.com
Cautionary Statement for purposes of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, growth opportunities, new accounts, customer base, market share, test volume and sales and marketing strategies) may be “forward looking” statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company’s sales and marketing team, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company’s filings with the Securities and Exchange Commission.
PSYCHEMEDICS CORPORATION
STATEMENTS OF INCOME
(in thousands, except per share amounts)
UNAUDITED
STATEMENTS OF INCOME
(in thousands, except per share amounts)
UNAUDITED
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2008 | 2007 | 2008 | 2007 | |||||||||||||
| Revenue | $ | 6,211 | $ | 6,497 | $ | 11,920 | $ | 12,214 | ||||||||
| Cost of revenue | 2,435 | 2,387 | 4,822 | 4,842 | ||||||||||||
| Gross profit | 3,776 | 4,110 | 7,098 | 7,372 | ||||||||||||
| Expenses: | ||||||||||||||||
| General and administrative | 1,095 | 1,029 | 2,117 | 1,861 | ||||||||||||
| Marketing and selling | 902 | 807 | 1,701 | 1,512 | ||||||||||||
| Research and development | 120 | 161 | 238 | 256 | ||||||||||||
| 2,117 | 1,997 | 4,056 | 3,629 | |||||||||||||
| Operating income | 1,659 | 2,113 | 3,042 | 3,743 | ||||||||||||
| Interest income | 73 | 101 | 185 | 197 | ||||||||||||
| Income before income taxes | 1,732 | 2,214 | 3,227 | 3,940 | ||||||||||||
| Provision for income taxes | 699 | 882 | 1,304 | 1,573 | ||||||||||||
| Net income | $ | 1,033 | $ | 1,332 | $ | 1,923 | $ | 2,367 | ||||||||
| Basic net income per share | $ | 0.20 | $ | 0.26 | $ | 0.37 | $ | 0.46 | ||||||||
| Diluted net income per share | $ | 0.20 | $ | 0.25 | $ | 0.36 | $ | 0.45 | ||||||||
| Dividends declared per share | $ | 0.17 | $ | 0.15 | $ | 0.32 | $ | 0.275 | ||||||||
| Weighted average common shares outstanding, basic | 5,224 | 5,172 | 5,222 | 5,191 | ||||||||||||
| Weighted average common shares outstanding, diluted | 5,279 | 5,237 | 5,277 | 5,260 | ||||||||||||
PSYCHEMEDICS CORPORATION
BALANCE SHEETS
(in thousands, except per share amounts)
BALANCE SHEETS
(in thousands, except per share amounts)
| June 30, | December 31, | |||||||
| 2008 | 2007 | |||||||
| (Unaudited) | ||||||||
ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 7,118 | $ | 6,097 | ||||
| Short-term investments | 200 | 3,875 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $238 in 2008 and $235 in 2007 | 3,876 | 3,555 | ||||||
| Prepaid expenses and other current assets | 955 | 499 | ||||||
| Deferred tax assets | 491 | 429 | ||||||
| Total current assets | 12,640 | 14,455 | ||||||
| Property and equipment | ||||||||
| Equipment and leasehold improvements, at cost | 10,838 | 10,793 | ||||||
| Less — Accumulated depreciation and amortization | (10,143 | ) | (9,977 | ) | ||||
| 695 | 816 | |||||||
| Deferred tax asset | 231 | 231 | ||||||
| Long-term investments | 2,200 | — | ||||||
| Other assets | 77 | 59 | ||||||
| Total assets | $ | 15,843 | $ | 15,561 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 583 | $ | 489 | ||||
| Accrued expenses | 965 | 951 | ||||||
| Deferred revenue | 193 | 243 | ||||||
| Total current liabilities | 1,741 | 1,683 | ||||||
| Shareholders’ equity: | ||||||||
| Preferred stock, $0.005 par value; 873 shares authorized, no shares issued or outstanding | — | — | ||||||
| Common stock, $0.005 par value; 50,000 shares authorized, 5,843 shares issued in 2008 and 5,812 shares issued in 2007 | 29 | 29 | ||||||
| Paid-in capital | 26,897 | 26,540 | ||||||
| Less — Treasury stock, at cost, 610 shares in 2008 and 586 shares in 2007 | (9,545 | ) | (9,164 | ) | ||||
| Accumulated deficit | (3,279 | ) | (3,527 | ) | ||||
| Total shareholders’ equity | 14,102 | 13,878 | ||||||
| Total liabilities and shareholders’ equity | $ | 15,843 | $ | 15,561 | ||||